Iran

Iran appears to have a small but real research footprint around ketamine, particularly in depression and peripartum settings, with published studies from Iranian universities and hospitals in Tehran, Zanjan, Sanandaj and Shiraz. The visible evidence is centred on clinician-led academic work rather than a commercial psychedelic-treatment market.

Ask Blossom about this country

Key Insights

A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Iran.

1
The strongest visible psychedelic-adjacent activity in Iran is ketamine research, not patient access to approved psychedelic medicines.
2
Peripartum ketamine appears to be a recurring research theme, suggesting interest in obstetric or postpartum indications alongside psychiatry.
3
The institutional footprint is academic and hospital-based, which implies clinical capability but not a broader regulated therapeutic market.
4
Iran's drug-control environment remains a major barrier to any non-medical psychedelic access, so research visibility does not translate into general availability.
5
The absence of linked stakeholders and events suggests a thin public ecosystem around psychedelic medicine rather than an organised national programme.

Research Snapshot

Blossom currently tracks 2 psychedelic clinical trials connected to Iran.

Active trials: 0
Total trials: 2
Stakeholders: 0
Events: 0

Top Compounds

Ketamine(2)

Medical Access Snapshot

Iran maintains strict national drug control laws that broadly prohibit recreational and unregulated use of classical psychedelics; however, ketamine is widely used and studied within Iran's formal medical system as an anesthetic and for perioperative/analgesic indications. There is no publicly available evidence of regulatory approval or routine reimbursement in Iran for licensed psychedelic therapeutics such as esketamine (Spravato) or for approved medical uses of psilocybin/MDMA; other classic psychedelics are effectively prohibited outside of approved...

View trials→Open access guide→

Regulatory Status

Publicly available evidence points to a strict controlled-drug environment in which recreational and unregulated use of classic psychedelics is prohibited, while ketamine is used within formal medical care and researched in hospitals. I did not find public evidence of routine access pathways for licensed psychedelic therapeutics such as psilocybin, MDMA or esketamine in Iran; if any exceptional medical or research authorisations exist, they are not clearly visible in the sources reviewed, so access should be treated as highly restricted and partly uncertain.